A vaccine targeting mutant IDH1 in newly diagnosed glioma.

ABSTRACT: Mutated isocitrate dehydrogenase 1 (IDH1) defines a molecularly distinct subtype of diffuse glioma^1-3. The most common IDH1 mutation in gliomas affects codon 132 and encodes IDH1(R132H), which harbours a shared clonal neoepitope that is presented on major histocompatibility complex (MHC) class II^4,5. An IDH1(R132H)-specific peptide vaccine (IDH1-vac) induces specific therapeutic T helper cell responses that are effective against IDH1(R132H)⁺ tumours in syngeneic MHC-humanized mice^4,6-8. Here we describe a multicentre, single-arm, open-label, first-in-humans phase I trial that we carried out in 33 patients with newly diagnosed World Health Organization grade 3 and 4 IDH1(R132H)⁺ astrocytomas (Neurooncology Working Group of the German Ca

SUBMITTER: Platten M 

PROVIDER: S-EPMC8046668 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature